Literature DB >> 10836621

Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis.

T Sharshar1, S Chevret, M Mazighi, P Chillet, G Huberfeld, C Berreotta, M Houfani, P Gajdos.   

Abstract

Valid and reliable measurements of muscle impairment are needed to assess therapeutic efficacy in patients with generalized myasthenia gravis (MG). In 22 patients we compared the validity and interobserver reliability of two scoring methods commonly used as main endpoints in clinical trials, i.e., the Myasthenic Muscle Score (MMS) ranging from 0 to 100 (normal) and the Quantified Myasthenia Gravis Strength Score (QMGSS) ranging from 0 (normal) to 39. Each score is correlated more with functional scale and less with the patient's self-evaluation. Using intraclass correlation we found strong agreement between observers for both the MMS (r = 0.906) and the QMGSS (r = 0.905). The correlation between MMS and QGMSS was high (r = 0.87). The reliability of neither score depended on any specific item, since the removal of individual items did not significantly alter the intraclass correlation coefficient (ranging from 0.86 to 0.93).

Entities:  

Mesh:

Year:  2000        PMID: 10836621     DOI: 10.1007/s004150050585

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

2.  CD19+ Tim-1+ B cells are decreased and negatively correlated with disease severity in Myasthenia Gravis patients.

Authors:  Yong Zhang; Xiuying Zhang; Yan Xia; Xiao Jia; Hao Li; Yanyan Zhang; Zhen Shao; Ning Xin; Mingfeng Guo; Jing Chen; ShuangShuang Zheng; YuZhong Wang; Linlin Fu; Chenghua Xiao; Deqin Geng; Yonghai Liu; Guiyun Cui; Ruiguo Dong; Xiaoyu Huang; Tingyan Yu
Journal:  Immunol Res       Date:  2016-12       Impact factor: 2.829

3.  Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

Authors:  Y-Z Wang; F-F Tian; M Yan; J-M Zhang; Q Liu; J-Y Lu; W-B Zhou; H Yang; J Li
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis.

Authors:  Yu-Zhong Wang; Mei Yan; Fa-Fa Tian; Jun-Mei Zhang; Qun Liu; Huan Yang; Wen-Bin Zhou; Jing Li
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

6.  Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis.

Authors:  Alberto Raggi; Matilde Leonardi; Carlo Antozzi; Paolo Confalonieri; Lorenzo Maggi; Ferdinando Cornelio; Renato Mantegazza
Journal:  Neurol Sci       Date:  2009-10-09       Impact factor: 3.307

7.  A conceptual framework for evaluating impairments in myasthenia gravis.

Authors:  Carolina Barnett; Vera Bril; Moira Kapral; Abhaya Kulkarni; Aileen M Davis
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

8.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

9.  A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis.

Authors:  Karima Habbout; Hugo Poulin; François Rivier; Serena Giuliano; Damien Sternberg; Bertrand Fontaine; Bruno Eymard; Raul Juntas Morales; Bernard Echenne; Louise King; Michael G Hanna; Roope Männikkö; Mohamed Chahine; Sophie Nicole; Said Bendahhou
Journal:  Neurology       Date:  2015-12-11       Impact factor: 9.910

10.  Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study.

Authors:  Sarah Hoffmann; Jana Siedler; Alexander U Brandt; Sophie K Piper; Siegfried Kohler; Christian Sass; Friedemann Paul; Ralf Reilmann; Andreas Meisel
Journal:  BMC Neurol       Date:  2015-12-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.